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Abstract
Background: The purpose of this study was to assess the feasibility and accuracy of sentinel lymph nodes (SLNs)
detection using 99mTc phytate in predicting pelvic lymph nodes status for radical abdominal trachelectomy (RAT)
in patients with early stage cervical cancer.
Methods: Sixty-eight women with stage IA2-IB1 cervical cancer and scheduled to undergo fertility-sparing surgery
enrolled in this study. 99mTc-labeled phytate was injected before surgery. Intraoperatively, SLNs were identified,
excised, and submitted to fast frozen section. Systematic bilateral pelvic lymphadenectomy and/or para-aortic
lymph node dissection was performed. Then RAT was performed in patients with negative SLNs. All nodes were
sent for routine pathological examination and immunostained with anti-cytokeratin antibody to detect
micrometastases. Outcomes of follow up and fertility were observed.
Results: SLNs were identified in 64 of 68 patients (94.1%). Of these, SLNs of 8 patients (11.8%) were positive on
frozen sections and proved to be metastasis by final pathologic examination. The sensitivity, accuracy, and false
negative rates were 100%, 100%, and 0%, respectively. All 60 patients with negative SLN underwent RAT
successfully. Two relapses occurred and no one died of tumor progression during follow-up. Five of the 15 patients
with procreative desire conceived 8 pregnancies (3 term delivery, 2 premature birth, 1 spontaneous abortion, and 2
were still in the duration of pregnancy) after surgery.
Conclusions: The identification of SLN using 99mTc-labeled phytate is accurate and safe to assess pelvic nodes
status in patients with early cervical cancer. SLNs biopsy guided RAT is feasible for patients who desire to have
fertility preservation.
Background
Cervical cancer is clinically classified according to the
International Federation of Gynaecology and Obstetrics
(FIGO) clinical staging system. Although the system
does not include evaluation of lymph node involvement,
lymph node status is one of the most important prog-
nostic factors in patients with early stage cervical cancer
[1-3]. Abdominal radical hysterectomy (RAH) with pel-
vic lymph node dissection remains the standard of care
for early stage cervical cancer [4]. In recent years,
radical trachelectomy with pelvic lymphadenectomy is
offered to young women with minimally invasive cervi-
cal cancer (stage IB1 or lower) with preservation of the
uterus in order to maintain fertility [5-7]. This proce-
dure involves a pelvic lymph node dissection and then
the surgical resection of the affected cervix and the
upper vagina with an adequate margin, and 2/3 of the
cardinal and uterosacral ligaments. This is then followed
by an endocervical and endometrial sampling above the
radical trachelectomy specimen with intraoperative
pathologic evaluation of surgical margins.
The sentinel lymph node (SLN) is the first node draining
the lymphatic flow from a primary tumor, and represents
the status of lymphatic spread [8-10]. Negative SLNs may
* Correspondence: jnsd2000@yahoo.cn
Department of Gynecologic Oncology, Shandong Cancer Hospital, Jinan
250117; Shandong Academy of Medical Science, Jinan 250012; Shandong
University, Jinan, 250012; P. R. China
Du et al. BMC Cancer 2011, 11:157
http://www.biomedcentral.com/1471-2407/11/157
© 2011 Du et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.basically exclude the possibility of the lymph node metas-
tasis of pelvic and other location, and, only on this base,
RAT can be considered. Therefore, identification of SLN
using 99mTc-labeled phytate can provide a good indica-
tion of the feasibility and safety to perform RAT. Women
with cervical cancer, particularly younger women who
wish to preserve reproductive potential, may be able to
avoid radical surgery if sentinel node biopsy is first used to
determine the most appropriate treatment option.
The purpose of this study was to assess the feasibility
and accuracy of the SLN detection procedure using
99mTc phytate to guide RAT in patients with early stage
cervical cancer. We hypothesis that if the SLN concept is
valid in cervical cancer, most patients could avoid pelvic
lymphadenectomy when the absence of metastasis is
intraoperatively confirmedi nt h eS L N .T h i sw o u l dd e f i -
nitely benefit many patients by avoiding radical hysterect-
omy and invasive lymphadenectomy, thus improving life
quality and decreasing surgical complications.
Methods
Patients and methods
Between March 2003 and December 2009, 68 patients
with FIGO stage IA2-IB1 cervical cancer and scheduled
to undergo fertility-sparing surgery at the Shandong
Cancer Hospital and Institute participated in this study.
All patients underwent total pelvic lymphadenectomy.
T h ec r i t e r i af o rp r e s e r v i n gt h eb o d yo ft h eu t e r u sa n d
part of the cervix were as follows: histologic diagnosis of
squamous cell carcinoma; fertile age; a desire for future
fertility; stage IA2 or IB1; and a cranial extent that
would allow for preservation of at least 1 cm of the
endocervical canal. The size of the tumor, its location,
and cranial extent were assessed in all patients by a
combination of magnetic resonance imaging and trans-
rectal ultrasound. The study was approved by the insti-
tutional review board, and all patients enrolled in this
study provided written informed consent before surgery.
Patient characteristics are summarized in Table 1.
After the incision is taken down and the specimen is
removed, the dilator is kept within the isthmus and a cerc-
lage suture of non-absorbable no. 10 silk suture is per-
formed with 4 or 5 good bites approximately 0.5 cm
proximal to the distal end of the isthmus. After surgery, all
women were followed up at regular intervals, and com-
bined oral contraceptives were recommended in case of
sexual activity. The patients were advised to wait a mini-
mum of 6 months after the procedure, with at least 2 con-
secutive normal cytology samples, before trying to conceive.
SLN identification
SLNs were detected with an isotope injection technique
into the uterine cervix. On the day before surgery, we
injected fluid containing 2.5 ml (100.0 MBq) of
99mTechnetium-labeled sulfur colloid subepithelially into
four quadrants (3, 6, 9, and 12 o’clock positions) of the
cervix. The diameter of particle is ranging from 50 to 100
nm. The SLNs were identified intraoperatively by a hand-
held gamma detector probe (Neoprobe, neo2000TM,
AR-MED, Ltd.) scanning the pelvic side wall, presacral
area, and para-aortic lymph node area. Radioactive hot
n o d e so nt h eb a s i so fc o u n t sm o r et h a n1 0 - f o l da b o v e
background level were defined as SLNs [11,12]. Then the
SLNs were excised with safety margins and submitted to
fast frozen section. The radioactivity of the tissue was
measured in vivo and after excision, as well as the radio-
activity of the surgical bed, to confirm that the marked
lesion had been fully excised. After removal of the SLNs,
bilateral pelvic lymphadenectomy was routinely done.
RAT was performed if the SLNs were negative. When
metastasis was found in the frozen section, hysterectomy
and/or para-aortic lymphadenectomy was done to deter-
mine the boundaries. Surgical specimens were examined
using routine hematoxylin and eosin staining.
Immunohistochemical staining
All surgically removed lymph nodes including SLNs
were immunostained with anti-cytokeratin antibody to
detect micrometastases. The intensity of protein expres-
sion was evaluated using OPTIMAS 6.5 software.
Adjuvant chemotherapy
Patients who exhibited one high risk factors according
to the pathologic diagnosis received 4 to 6 cycles of
Table 1 Characteristics of the 68 patients
Characteristics No. of patients
(%)
Mean age (range) 28 yr (18-41)
International Federation of Gynaecology and
Obstetrics (FIGO) stage
IA1 3 (4.4)
IA2 28 (41.2)
IB1 37 (54.4)
≤1.0 cm 12 (32.5)
>1.0 cm, ≤2.0 cm 13 (35.1)
>2.0 cm, ≤3.0 cm 6 (16.2)
>3.0 cm, ≤4.0 cm 6 (16.2)
Cell differentiation
Well 45 (66.2)
Moderate 14 (20.6)
Poor 9 (13.2)
Childbearing history
0 38 (55.9)
1 27 (39.7)
≥2 3 (4.4)
Total 68
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tures were as follows: poor differentiation, deep stromal
invasion, and maximal tumor diameter >2 cm. Adjuvant
chemotherapy included either a combination of cisplatin
(25 mg/m
2, d1-3), vincristine (1.25 mg/m
2, d1, d8), and
bleomycin (20 mg/m
2, d1-3) (combination PVB), or a
combination of cisplatin (25 mg/m
2, d1-3), etoposide
(70 mg/m
2, d1-5), and bleomycin (20 mg/m
2,d 1 - 3 )
(combination PEB).
Follow-up evaluation
Upon treatment completion, patients were evaluated
monthly for the first 3 months, every 3 months for the
first year, every 6 months during the following two
years, and annually thereafter. At each visit, a physical
and pelvic examination, blood counts, and chest x-rays
were performed. Scans of the abdomen and pelvic
region were conducted by Ultrasound (US), computed
tomography (CT) scan and/or PET-CT. Survival, recur-
rence, pregnancy and childbearing information were
obtained from personal contact with the patient or her
family. Overall survival was calculated from the date of
diagnosis. Surviving patients were censored on the date
of last follow-up.
Statistical analysis
Continuous variables were compared with Student’st
test, and categorical variables were compared using chi
square test or Fisher’s exact test, as appropriate. Statisti-
cal significance was defined at a level of P < 0.05. All
analyses were performed using SPSS version 13.0 (SPSS
Inc., Chicago, IL).
Results
SLN detection results
The median age was 33 years (ranging from 18 to 41
yrs). A total of 274 lymph nodes were detected as SLNs
in 64 of 68 patients, the detection rate was 94.1% (64/
68). The number of SLNs identified per patient was 0 in
4 cases, one in 2 cases, two in 6 cases, three in 31 cases,
four in 14 cases, five in 11 cases, and six in 8 cases. As
shown in table 2, the most common site for SLN detec-
tion was the obturator (138 nodes), detected in 45.6%
(31/68) patients; followed by the external iliac (86
nodes), detected in 27.9% (19/68) patients; the internal
iliac (35 nodes) in 13.2% (9/68); the common iliac (13
nodes) in 5.9% (4/68); and the cardinal ligament (2
nodes) in 1.5% (1/68). No SLN was found in the presa-
cral or para-aortic area. Bilateral pelvic SLNs were
detected in 28 of 68 patients (41.2%). The relationships
between SLN detection rate and various clinical charac-
teristics are shown in table 3. The SLN detection rate
was statistically lower in patients with tumor sizes >3
cm than in patients with tumor sizes ≤3 cm (66.7% vs.
96.8%, P = 0.004). Age, FIGO stage, cell differentiation,
and preoperative conization did not affect SLN detect-
ability (P = 0.153, 0.106, 0.248, and 0.266, respectively).
The results of the frozen sections were identical to those
of the permanent staining. As shown in Figure 1, 13
pathologically proven positive nodes were found in 8
(9.3%) patients, which were all SLNs. Four patients had
unilateral SLNs and four had bilateral SLNs. Six patients
had unilateral lymph node metastasis and two had bilateral
metastasis. No false negative SLNs were obtained in frozen
section. The sensitivity was 100%, the accuracy and false
negative rate was 100% and 0%, respectively, and the nega-
tive predictive value of SLN was 100% (Table 4). All of
these eight patients with positive lymph nodes were
proved to be positive on frozen section. The results of
anti-keratinose immunohistochemical staining found no
missed micrometastasis in SLNs (data not shown).
Adjuvant chemotherapy and complications
A total of 88.2% (60/68) patients underwent RAT,
whereas 11.8% of patients (8/68) ended up with RAH
due to primarily positive SLNs. Patients who underwent
RAT and demonstrated high risk factor according to the
pathologic diagnosis received 4 cycles (n = 13) or 6
cycles (n = 8) of adjuvant chemotherapy. Of these
patients, 12 received chemotherapy of combination PVB
and 9 received PEB chemotherapy. For those patients
who underwent RAH, 3 received 5 weeks of concurrent
chemoradiotherapy and 5 received adjuvant radiotherapy
after surgery (data not shown in this paper).
Table 2 The localization and status of the sentinel lymph
nodes
SLN detection 64/68 (94.1%)
Total number of SLN 274
Localization of SLN
Common iliac 13 (4.7%)
External iliac 86 (31.4%)
Internal iliac 35 (12.8%)
Obturator 138 (50.3%)
Cardinal ligament 2 (0.8%)
Sacral 0
Para-aortic 0
Latus of pelvic SLNs
Unilateral 36/68 (52.9%)
Common iliac 3/36 (8.3%)
External iliac 8/36 (22.2%)
Interanl iliac 4/36 (11.1%)
Obturator 19/36 (52.8%)
Cardinal ligament 2/36 (5.6%)
Bilateral 28/68 (41.2%)
None 4 (5.9%)
SLN, Sentinel lymph node.
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Page 3 of 7Permanent cerclage during trachelectomy and cerclage
at the beginning of pregnancy were placed in 29 and 3
patients, respectively. Surgical complications included
post-trachelectomy stenosis of the neo-cervix in 17 of
60 (28.3%) patients, leg lymphedema in 7 of 68 (10.3%)
patients, infected pelvic lymphocyst in 5 of 68 (7.3%)
patients, and amenorrhea in 3 of 60 (5%) patients.
Side-effects of adjuvant chemotherapy mainly included
myelosuppression and gastrointestinal disorders. Grade
3/4 leukopenia occurred in 3 of 21 (14.3%) patients.
One (4.8%) patient experienced grade 3 chemotherapy-
induced vomiting, nausea and anorexia.
Outcomes of follow-up
The median time of follow-up was 38 months (range, 3-
84 months). Up to March 2010, 7 of 68 (10.3%) patients
were lost, leading to follow-up rates amounting to
89.7%. Of the 7 patients lost, 5 were out of contact,
another 2 gave up the reexamination. Thus, these
patients’ responses were not included in the data analy-
sis. The patients lost to follow-up presented no statisti-
cally significant differences from the patients who
remained in the study in terms of age (P = 0.327),
Table 3 Relationships between SLN detection rate and various clinical characteristics
Characteristic No. of patients No. of cases with SLNs detected (%) SLN detected P value
Unilateral Bilateral None
Age (year) 0.153
≤25 9 9 5 4 0
>25, ≤30 22 20 12 8 2
>30, ≤35 20 19 9 10 1
>35 17 16 10 6 1
FIGO stage 0.106
IA1 3 3 3 0 0
IA2 28 26 16 10 2
IB1 37 35 17 18 2
Differentiation 0.248
Well 45 44 24 20 1
Moderate 14 12 8 4 2
Poor 9 8 4 4 1
Tumor size 0.004
≤1.0 cm 41 40 22 18 1
>1.0 cm,≤2.0 cm 13 12 7 5 1
>2.0 cm,≤3.0 cm 8 8 4 4 0
>3.0 cm 6 4 3 1 2
Preoperative conization 0.266
Yes 19 18 11 7 1
No 49 46 25 21 3
SLN, sentinel lymph node; FIGO, International Federation of Gynecology and Obstetrics.
Figure 1 Outcome of sentinel lymph node biopsy in 68
patients with stage IA2-IB1 cervical cancer. SLNs were identified
in 64 of 68 patients. Of these, SLNs of 8 patients were positive on
frozen sections and proved to be metastasis by final pathologic
examination. No false negative SLNs were obtained in frozen
section.
Table 4 Sentinel lymph node biopsy for evaluation of
pelvic lymph node metastasis
SLN Pathologic diagnosis
Positive (+) Negative (-) Total
Positive (+) 8 0 8
Positive (-) 0 56 56
Total 8 56 64
Results No. of Patients % of Total 95% CI
Sensitivity 8/8 100 71-100
Accuracy 64/64 100 89-100
Positive predictive value 100
Negative predictive value 100
SLN, sentinel lymph node
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preoperative conization (P = 0.169), or complications (P
= 0.354, data not shown).
Two relapses occurred at 8 and 17 months after the
diagnosis, respectively. One patient occurred with para-
aortic lymph node (PALN) metastasis and the other
with pelvic recurrence. No one died of tumor progres-
sion during follow-up. The actuarial overall survival and
disease-free survival at 3 years were 100% and 96.7%,
respectively.
Five of the 15 patients who had procreative desire
conceived a total of 8 pregnancies within 2 years after
surgery. Of the 8 pregnancies, 3 were presented as term
delivery, 2 premature births, 1 spontaneous abortion,
and 2 were still in the duration of their pregnancies.
Two premature births ocurred in 31 and 33 week of
pregnancy for premature rupture of membranes
(PROM) and the newborns developed well.
Discussion
In previous studies, SLN detection reportedly had sensi-
tivity ranging from 71% to 100%, a specificity of 100%,
and a diagnostic accuracy ranging from 75% to 100% for
predicting disease status in the remaining regional
lymph node basin [13-16]. In this study, a total of 274
lymph nodes were detected as SLNs in 64 of 68 patients
(94.1%). Of these, 8 (11.8%) SLNs were positive and 56
(88.2%) SLNs were negative on intraoperative frozen
sections. Final pathologic examination revealed that all 8
patients with positive SLNs had lymph node metastasis.
The results of the frozen section were parallel to those
of the anti-keratinose immunohistochemical staining.
No false negative SLNs were obtained. Our results
demonstrated that SLN biopsy was highly sensitive
(100%) and accurate (100%) for diagnosing metastases in
stage IA2-IB1 cervical cancer. The false negative rate
was 0% and the negative predictive value of SLN was
100%. Thus, this study demonstrates that the SLN
detection guided RAT is accurate, safe, and efficient to
assess pelvic nodes status in patients with early cervical
cancer. With careful preoperative evaluation for eligible
patients and reliable intraoperative pathological investi-
gation of SLNs, sentinel node navigation surgery can
provide large benefits for select patients who desire to
have fertility preservation.
Plentl et al [17] described a typical pattern of lympha-
tic drainage from cervix to regional lymph nodes.
According to the pattern, the parametric node is the
first draining node in cervical cancer. But the parametric
node is too close to the cervix to be detected. Some stu-
dies [18,19] reported that 80% of SLNs were located in
pelvic structures and the most common site for SLN
detection was the external iliac. Our findings were simi-
lar to those reports, exceptt h a tt h em o s tS L N sw e r e
located in obturator (50.4%, 138/274). Only 31.4% (86/
274) SLNs were located in the external iliac. We also
detected 35 SLNs in the internal iliac, 13 in common
iliac, and 2 in cardinal ligament. No SLNs were found in
the parametric region, presacral or para-aortic areas.
Unilateral pelvic SLNs were detected in 52.9% of 68
patients in our study. Possible explanations may include
that the lymphatic drainage of SLN could occur in one
side of pelvis. Similar results were reported by previous
studies [20,21].
SLN detection rate was reported to be associated to
stage, tumor size, histologic type, preoperative treat-
ment, and a history of preoperative conization. The rela-
tionships between SLN detection rate and various
clinical characteristics were also investigated in this
study. Our results showed that SLN detection was asso-
ciated with tumor size. SLN detection rate was statisti-
cally lower in patients with tumor sizes >3 cm than in
patients with tumor sizes ≤3c m( 6 6 . 7 %v s .9 6 . 8 % ,P =
0.004). A similar trend was reported by Wydra et al.
[22].
Different authors hold controversial opinions about
whether the preoperative conization has an effect on the
detection rate of SLN. Dargent et al. [23] reported that
the SLN detection rate, of patients with preoperative
conization, was 74%; this was lower than that of patients
without preoperative conization (86%). Similar results
were reported by Seong et al. [24]. On the contrary,
some other authors found that there has been no corre-
lation noted between the preoperative conization and
the SLN detection rate [15,25]. Likewise, our data show
that detection failure was not influenced by the preo-
perative conization (P = 0.266).
For patients who have high risk factors, such as poor
differentiation, deep stromal invasion, or maximal tumor
diameter >2 cm, postoperative adjunctive therapy is
necessary. Radiotherapy or concurrent chemoradiother-
apy are often performed in these patients. However,
radiotherapy may destroy the fertility of those patients
who underwent RAT, resulting in the failure of fertility
preservation. To deal with this problem, we did further
studies on the alternative postoperative treatment
method for these patients. In one of our previous stu-
dies, we compared the efficacy and safety of simple che-
motherapy with combined radiotherapy and
chemotherapy in 58 patients who exhibited high risk
factors after RAH or RAT. Our results revealed that
there was no significant difference between the two
groups (data not shown). A similar result was obtained
in the present study.
Previous studies reported that the recurrence rates of
cervical cancer in patients who underwent RAT were
comparable to patients who carried out RAH. These
recurrence rates ranged from 0% to 8% [25,26]. Similar
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rence rate of 3.3% from two patients who relapsed dur-
ing follow-up (median time of 38 months).
Koliopoulos et al. [25] reported that 210 women who
underwent radical trachelectomy had 35 live births
after surgery. Shepherd et al. [26] reported that of the
900 cases of women who underwent RAT, over 300
became pregnant resulting in 195 live births. As we
know, anticancer drugs injure the female reproductive
system through ovarian follicular and stromal damage
[27]. With conventional chemotherapy, there is signifi-
cant differences in ovarian failure rate according to
patients age, disease for which patients are treated for,
and the drugs used. Some reports discussed the influ-
ence of adjuvant chemotherapy on female fertility.
Morice et al. [28] reported that the impact of che-
motherapy on a woman’s fertility depends on her age
and the types and doses of the drugs used. Alkylating
agents have the biggest negative impact on ovarian
function. Protecting fertility potential in females
exposed to chemotherapy with GnRH agonists, IVF
and embryo cryopreservation or cryopreservation of
ovarian tissue is practiced in recent years. Lawrenz et
al. [29] reported 1,080 patients received such therapy
received 2,417 oocytes and the fertilisation rate per
received oocyte was 61.3%. In the present study, five of
the 15 patients who had procreative desire were able
to conceive after surgery for a total of 8 pregnancies.
Premature rupture of the membranes is also a risk,
with 10% of babies being born significantly premature.
Of those pregnancies in our study, 2 was a premature
birth due to the PROM. Cerclage during trachelectomy
or at the beginning of pregnancy may help to reduce
the rate of miscarriage.
Conclusions
In conclusion, the current study indicated that, SLN
procedure using 99mTc-labeled phytate is a minimally
invasive, accurate technique to assess pelvic lymph node
status in patients with early cervical cancer. Lymph
node mapping using SLN biopsy may help select
patients who would benefit from such fertility-sparing
surgery. Tumor size is an important factor influencing
the success rate of SLN detection. We believe that SLN
biopsy guiding RAT is feasible for young patients who
desire to have fertility preservation. However, further
research is needed to assess the practicality of using
these techniques. In addition, long-term survival data
for patients with negative sentinel node biopsy are
required.
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